PortalPublikationenEntecavir treatment for chronic hepatitis B

Entecavir treatment for chronic hepatitis B

Standard

Entecavir treatment for chronic hepatitis B : adaptation is not needed for the majority of naïve patients with a partial virological response. / Zoutendijk, Roeland; Reijnders, Jurriën G P; Brown, Ashley; Zoulim, Fabien; Mutimer, David; Deterding, Katja; Petersen, Jörg; Hofmann, Wolf Peter; Buti, Maria; Santantonio, Teresa; van Bömmel, Florian; Pradat, Pierre; Oo, Ye; Lütgehetmann, Marc; Berg, Thomas; Hansen, Bettina E; Wedemeyer, Heiner; Janssen, Harry L A; VIRGIL Surveillance Study Group.

in: HEPATOLOGY, Jahrgang 54, Nr. 2, 08.2011, S. 443-51.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Zoutendijk, R, Reijnders, JGP, Brown, A, Zoulim, F, Mutimer, D, Deterding, K, Petersen, J, Hofmann, WP, Buti, M, Santantonio, T, van Bömmel, F, Pradat, P, Oo, Y, Lütgehetmann, M, Berg, T, Hansen, BE, Wedemeyer, H, Janssen, HLA & VIRGIL Surveillance Study Group 2011, 'Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response', HEPATOLOGY, Jg. 54, Nr. 2, S. 443-51. https://doi.org/10.1002/hep.24406

APA

Zoutendijk, R., Reijnders, J. G. P., Brown, A., Zoulim, F., Mutimer, D., Deterding, K., Petersen, J., Hofmann, W. P., Buti, M., Santantonio, T., van Bömmel, F., Pradat, P., Oo, Y., Lütgehetmann, M., Berg, T., Hansen, B. E., Wedemeyer, H., Janssen, H. L. A., & VIRGIL Surveillance Study Group (2011). Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. HEPATOLOGY, 54(2), 443-51. https://doi.org/10.1002/hep.24406

Vancouver

Zoutendijk R, Reijnders JGP, Brown A, Zoulim F, Mutimer D, Deterding K et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. HEPATOLOGY. 2011 Aug;54(2):443-51. https://doi.org/10.1002/hep.24406

Bibtex

@article{e19e53dd63dd42fda32b9411b6744b9c,
title = "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na{\"i}ve patients with a partial virological response",
abstract = "UNLABELLED: Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-na{\"i}ve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-na{\"i}ve CHB patients, particularly in those with detectable hepatitis B virus (HBV) DNA after 48 weeks, in whom treatment adaptation is suggested by current guidelines. In a multicenter cohort study, we investigated 333 CHB patients treated with entecavir monotherapy. The NA-na{\"i}ve population consisted of 243 patients, whereas 90 were NA-experienced. Virological response (VR) (HBV DNA<80 IU/mL) was achieved in 48%, 76%, and 90% of hepatitis B e antigen (HBeAg)-positive and in 89%, 98%, and 99% of HBeAg-negative NA-na{\"i}ve patients at weeks 48, 96, and 144, respectively. Thirty-six of 175 (21%) NA-na{\"i}ve patients with at least 48 weeks of follow-up had a detectable load at week 48 (partial virological response [PVR]). Twenty-nine (81%) patients with PVR reached VR during prolonged ETV monotherapy, and none of them developed ETV-resistance. Among 22 patients with HBV DNA<1,000 IU/mL at week 48, VR was achieved in 21 (95%) patients, compared with eight of 14 (57%) patients with HBV DNA≥1,000 IU/mL. Continuous HBV DNA decline was observed in most patients without VR during follow-up, and in three patients adherence was suboptimal according to the treating physician. ETV was safe and did not affect renal function or cause lactic acidosis.CONCLUSION: ETV monotherapy can be continued in NA-na{\"i}ve patients with detectable HBV DNA at week 48, particularly in those with a low viral load because long-term ETV leads to a virological response in the vast majority of patients.",
keywords = "Adult, Antiviral Agents, Cohort Studies, Female, Guanine, Hepatitis B, Chronic, Humans, Male, Prospective Studies, Time Factors, Treatment Outcome",
author = "Roeland Zoutendijk and Reijnders, {Jurri{\"e}n G P} and Ashley Brown and Fabien Zoulim and David Mutimer and Katja Deterding and J{\"o}rg Petersen and Hofmann, {Wolf Peter} and Maria Buti and Teresa Santantonio and {van B{\"o}mmel}, Florian and Pierre Pradat and Ye Oo and Marc L{\"u}tgehetmann and Thomas Berg and Hansen, {Bettina E} and Heiner Wedemeyer and Janssen, {Harry L A} and {VIRGIL Surveillance Study Group}",
note = "Copyright {\textcopyright} 2011 American Association for the Study of Liver Diseases.",
year = "2011",
month = aug,
doi = "10.1002/hep.24406",
language = "English",
volume = "54",
pages = "443--51",
journal = "HEPATOLOGY",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Entecavir treatment for chronic hepatitis B

T2 - adaptation is not needed for the majority of naïve patients with a partial virological response

AU - Zoutendijk, Roeland

AU - Reijnders, Jurriën G P

AU - Brown, Ashley

AU - Zoulim, Fabien

AU - Mutimer, David

AU - Deterding, Katja

AU - Petersen, Jörg

AU - Hofmann, Wolf Peter

AU - Buti, Maria

AU - Santantonio, Teresa

AU - van Bömmel, Florian

AU - Pradat, Pierre

AU - Oo, Ye

AU - Lütgehetmann, Marc

AU - Berg, Thomas

AU - Hansen, Bettina E

AU - Wedemeyer, Heiner

AU - Janssen, Harry L A

AU - VIRGIL Surveillance Study Group

N1 - Copyright © 2011 American Association for the Study of Liver Diseases.

PY - 2011/8

Y1 - 2011/8

N2 - UNLABELLED: Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV) DNA after 48 weeks, in whom treatment adaptation is suggested by current guidelines. In a multicenter cohort study, we investigated 333 CHB patients treated with entecavir monotherapy. The NA-naïve population consisted of 243 patients, whereas 90 were NA-experienced. Virological response (VR) (HBV DNA<80 IU/mL) was achieved in 48%, 76%, and 90% of hepatitis B e antigen (HBeAg)-positive and in 89%, 98%, and 99% of HBeAg-negative NA-naïve patients at weeks 48, 96, and 144, respectively. Thirty-six of 175 (21%) NA-naïve patients with at least 48 weeks of follow-up had a detectable load at week 48 (partial virological response [PVR]). Twenty-nine (81%) patients with PVR reached VR during prolonged ETV monotherapy, and none of them developed ETV-resistance. Among 22 patients with HBV DNA<1,000 IU/mL at week 48, VR was achieved in 21 (95%) patients, compared with eight of 14 (57%) patients with HBV DNA≥1,000 IU/mL. Continuous HBV DNA decline was observed in most patients without VR during follow-up, and in three patients adherence was suboptimal according to the treating physician. ETV was safe and did not affect renal function or cause lactic acidosis.CONCLUSION: ETV monotherapy can be continued in NA-naïve patients with detectable HBV DNA at week 48, particularly in those with a low viral load because long-term ETV leads to a virological response in the vast majority of patients.

AB - UNLABELLED: Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV) DNA after 48 weeks, in whom treatment adaptation is suggested by current guidelines. In a multicenter cohort study, we investigated 333 CHB patients treated with entecavir monotherapy. The NA-naïve population consisted of 243 patients, whereas 90 were NA-experienced. Virological response (VR) (HBV DNA<80 IU/mL) was achieved in 48%, 76%, and 90% of hepatitis B e antigen (HBeAg)-positive and in 89%, 98%, and 99% of HBeAg-negative NA-naïve patients at weeks 48, 96, and 144, respectively. Thirty-six of 175 (21%) NA-naïve patients with at least 48 weeks of follow-up had a detectable load at week 48 (partial virological response [PVR]). Twenty-nine (81%) patients with PVR reached VR during prolonged ETV monotherapy, and none of them developed ETV-resistance. Among 22 patients with HBV DNA<1,000 IU/mL at week 48, VR was achieved in 21 (95%) patients, compared with eight of 14 (57%) patients with HBV DNA≥1,000 IU/mL. Continuous HBV DNA decline was observed in most patients without VR during follow-up, and in three patients adherence was suboptimal according to the treating physician. ETV was safe and did not affect renal function or cause lactic acidosis.CONCLUSION: ETV monotherapy can be continued in NA-naïve patients with detectable HBV DNA at week 48, particularly in those with a low viral load because long-term ETV leads to a virological response in the vast majority of patients.

KW - Adult

KW - Antiviral Agents

KW - Cohort Studies

KW - Female

KW - Guanine

KW - Hepatitis B, Chronic

KW - Humans

KW - Male

KW - Prospective Studies

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1002/hep.24406

DO - 10.1002/hep.24406

M3 - SCORING: Journal article

C2 - 21563196

VL - 54

SP - 443

EP - 451

JO - HEPATOLOGY

JF - HEPATOLOGY

SN - 0270-9139

IS - 2

ER -